BAVARIAN NORDIC/S (BVNRY) Set to Announce Earnings on Friday

Share on StockTwits

BAVARIAN NORDIC/S (OTCMKTS:BVNRY) will post its quarterly earnings results before the market opens on Friday, November 9th. Analysts expect BAVARIAN NORDIC/S to post earnings of ($0.14) per share for the quarter.

BAVARIAN NORDIC/S (OTCMKTS:BVNRY) last issued its earnings results on Thursday, August 16th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.02). BAVARIAN NORDIC/S had a negative return on equity of 6.60% and a negative net margin of 18.41%. The company had revenue of $13.83 million for the quarter, compared to the consensus estimate of $10.40 million. On average, analysts expect BAVARIAN NORDIC/S to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Shares of BVNRY opened at $7.76 on Wednesday. BAVARIAN NORDIC/S has a 1 year low of $7.41 and a 1 year high of $14.00. The company has a current ratio of 5.35, a quick ratio of 5.07 and a debt-to-equity ratio of 0.18. The stock has a market cap of $748.30 million, a price-to-earnings ratio of 26.76 and a beta of 1.20.

Several equities analysts have recently weighed in on the company. ValuEngine upgraded BAVARIAN NORDIC/S from a “sell” rating to a “hold” rating in a report on Thursday, August 2nd. Zacks Investment Research upgraded BAVARIAN NORDIC/S from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a report on Wednesday, August 22nd.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Week Herald and is owned by of Week Herald. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at


Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus.

Featured Story: What is the Dividend Aristocrat Index?


Receive News & Ratings for BAVARIAN NORDIC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BAVARIAN NORDIC/S and related companies with's FREE daily email newsletter.

Leave a Reply